The efficacy of albendazole (ABZ) treatment for human neurocysticercosis (NCC) was assessed by using a monoclonal antibody-based parasite antigen detection ELISA which specifically detects the products of living cysticerci in human serum. The assay displayed 85% diagnostic sensitivity, detecting 39 of 46 NCC cases. Only patients with a single viable cyst or only enhancing lesions (degenerating parasites) were seronegative. Specificity of the assay was 92% (23/25) when tested in healthy Peruvian volunteers. In 'cured' patients, in whom all parasites died after ABZ therapy, parasite antigen levels fell sharply by 3 months post treatment. This pattern was not observed in patients refractory to treatment. The sensitivity of the assay with serum samples, and its ability to identify successfully treated patients, make this monoclonal antibody-based ELISA the test of choice for the follow-up of NCC cases.
|Number of pages||4|
|Journal||Transactions of the Royal Society of Tropical Medicine and Hygiene|
|State||Published - 2000|
Bibliographical noteFunding Information:
all the personnelo f the cysticercosilsa boratoryo f the Institute National de CienciasN eurologicasf or help in samplem anage-ment and data collection.T his study was funded in part by grants CT95-0002 from the INCO-DC programmeo f the European Union, FD-R-001107 from the Food and Drug Administration,a nd numbersU 19-A145431,T WOO598,a nd R03-AI-42037 from the National Institutesf or Health, USA. The authorsa lsoa cknowledgeth eBritish Council for supporti n the form of a Higher Education Link Project between the Universityo f Edinburgha ndt heU niversidadP eruanaC ayetano Heredia.
- Antigen detection
- Taenia solium